These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38470310)

  • 1. Risankizumab, a therapeutic alternative for psoriasis in people living with HIV.
    Estevinho T; Freitas E; Torres T
    J Int Med Res; 2024 Mar; 52(3):3000605241229324. PubMed ID: 38470310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case series.
    Orsini D; Maramao FS; Gargiulo L; Ibba L; Piscazzi F; Pacifico A; Latini A; Gianserra L; Cristaudo A; Costanzo A; Narcisi A
    Int J STD AIDS; 2024 Jan; 35(1):67-70. PubMed ID: 37691387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Successful treatment with risankizumab in a patient with psoriasis and HIV].
    Sanguinetti J; Suar L; Eimer L; Busso C
    Medicina (B Aires); 2022; 82(4):605-608. PubMed ID: 35904917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.
    Haugh IM; Preston AK; Kivelevitch DN; Menter AM
    Drug Des Devel Ther; 2018; 12():3879-3883. PubMed ID: 30518998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on risankizumab for the treatment of moderate to severe psoriasis.
    Al-Janabi A; Warren RB
    Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risankizumab to treat moderately to severely active Crohn's disease in adults: an evaluation of trials and data.
    Johnson AM; Loftus EV
    Expert Rev Gastroenterol Hepatol; 2023 Dec; 17(12):1169-1183. PubMed ID: 38095092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study.
    Hamm C; Ramsoondar N; McGillis M; Waugh M; Gooderham M; Giroux LL
    J Cutan Med Surg; 2023; 27(5):476-480. PubMed ID: 37559454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risankizumab in moderate-to-severe plaque psoriasis.
    Serrano L; Maloney V; Gordon KB
    Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IL 23 biologics for the treatment of plaque psoriasis.
    Vu A; Ulschmid C; Gordon KB
    Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A drug safety evaluation of risankizumab for psoriasis.
    Huang YW; Tsai TF
    Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risankizumab for the treatment of moderate to severe psoriasis.
    Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
    Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
    [No Abstract]   [Full Text] [Related]  

  • 16. Risankizumab for the treatment of psoriasis.
    Gu C; Yang J
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
    [No Abstract]   [Full Text] [Related]  

  • 17. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.
    Megna M; Potestio L; Ruggiero A; Camela E; Fabbrocini G
    Dermatol Ther; 2022 Jul; 35(7):e15524. PubMed ID: 35439341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.